FTO and acute myeloid leukemia: Inhibition of FTO by CS1 or CS2 significantly suppresses LSC self-renewal and promotes the immune response by suppressing the expression of the immune checkpoint gene LILRB4. They reverse TIE by abolishing the FTO-induced stability of LILRB4 mRNA and enhancing the sensitivity of AML cells to T-cell cytotoxicity [39].